Key Takeaways
- • Corporate healthcare M&A surged to $332 billion in 2017, rebounding from a 2016 dip, while private equity deal disclosure reached $42.6 billion across 265 transactions—the highest PE volume since 2007, up from 206 deals in 2016.
- • Intense competitive pressure constrained deal flow: PE funds faced crowded bidding environments against both corporate acquirers and rival funds, leaving many investors frustrated with deployment constraints despite record dry powder levels.
- • Valuations reached unsustainable levels for multiple expansion, forcing PE managers to shift strategy toward operational improvements and value creation rather than relying on exit multiple arbitrage to generate returns.
- • Deal creativity became essential: successful PE investors pursued carve-outs, add-ons, syndicated structures with co-investors, and public-to-private conversions to access scarce quality targets, while moving into less competitive segments including post-acute care, medical groups, medtech, and branded pharmaceuticals.
- • Disruptive forces reshaped investment thesis: PE firms began positioning portfolios to capitalize on digitalization, consumerism trends, and non-traditional entrants (notably Amazon), while simultaneously hedging reimbursement and competitive risks in healthcare-heavy subsectors.
Summary
The global healthcare private equity market in 2017–2018 entered a phase of structural transition characterized by record valuations, heightened competitive friction, and shifting strategic imperatives. Corporate healthcare M&A reached $332 billion in 2017 following a contraction in 2016, signaling robust underlying sector momentum. Private equity activity within this ecosystem reflected this vitality: disclosed deal value hit $42.6 billion with 265 completed transactions, marking the strongest volume since 2007 and a material increase from 206 deals in 2016. However, these headline figures masked underlying tension in the market.
The primary constraint was scarcity—quality healthcare assets suitable for PE ownership did not scale with available capital. Dry powder accumulation across healthcare-focused funds created a paradox: record capital availability collided with limited premium opportunities. Competitive tension intensified across bidding processes as PE firms, corporate buyers, and cross-border acquirers pursued the same targets. Many PE investors ended 2017 frustrated by deployment failure, unable to close sufficient deals despite favorable financing conditions and strong operational platforms within existing portfolios.
This imbalance drove valuation multiples to elevated levels, requiring strategic recalibration. PE managers recognized that traditional return models—predicated on multiple expansion at exit—had become unreliable. Instead, winning firms pivoted to operational leverage, cost optimization, and platform consolidation to generate returns. Simultaneously, PE investors demonstrated tactical flexibility through deal structuring innovation: carve-outs from larger corporate assets, bolt-on acquisition strategies within platforms, syndication with co-investors to share risk and increase bidding power, and selective use of public-market acquisitions to take companies private.
Given the scarcity of traditional "healthcare-light" targets in software, diagnostics, and distribution, PE firms moved upmarket into reimbursement-heavy segments including post-acute care, medical groups, medtech, and branded pharmaceuticals. This represented a willingness to accept regulatory and pricing risk in exchange for category-leading market positions in less saturated subsectors. Concurrently, the investment thesis evolved to address industry-wide disruption. PE investors began building capabilities around digital health transformation, direct-to-consumer care models, and the implications of technology-driven entrants—particularly Amazon's nascent healthcare initiatives. The strategic message was clear: disruption presented both opportunity and risk, and portfolio construction needed to hedge both scenarios simultaneously.
The primary constraint was scarcity—quality healthcare assets suitable for PE ownership did not scale with available capital. Dry powder accumulation across healthcare-focused funds created a paradox: record capital availability collided with limited premium opportunities. Competitive tension intensified across bidding processes as PE firms, corporate buyers, and cross-border acquirers pursued the same targets. Many PE investors ended 2017 frustrated by deployment failure, unable to close sufficient deals despite favorable financing conditions and strong operational platforms within existing portfolios.
This imbalance drove valuation multiples to elevated levels, requiring strategic recalibration. PE managers recognized that traditional return models—predicated on multiple expansion at exit—had become unreliable. Instead, winning firms pivoted to operational leverage, cost optimization, and platform consolidation to generate returns. Simultaneously, PE investors demonstrated tactical flexibility through deal structuring innovation: carve-outs from larger corporate assets, bolt-on acquisition strategies within platforms, syndication with co-investors to share risk and increase bidding power, and selective use of public-market acquisitions to take companies private.
Given the scarcity of traditional "healthcare-light" targets in software, diagnostics, and distribution, PE firms moved upmarket into reimbursement-heavy segments including post-acute care, medical groups, medtech, and branded pharmaceuticals. This represented a willingness to accept regulatory and pricing risk in exchange for category-leading market positions in less saturated subsectors. Concurrently, the investment thesis evolved to address industry-wide disruption. PE investors began building capabilities around digital health transformation, direct-to-consumer care models, and the implications of technology-driven entrants—particularly Amazon's nascent healthcare initiatives. The strategic message was clear: disruption presented both opportunity and risk, and portfolio construction needed to hedge both scenarios simultaneously.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.